Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cellectis

- PMLiVE

EMA grants AZ’s Vaxzevria COVID-19 vaccine full marketing authorisation

Vaxzevria has been shown to be effective against all forms of COVID-19

- PMLiVE

AbbVie submits application for lymphoma therapy epcoritamab to EMA

Phase 2 trial showed an overall response rate of 63% and a complete response rate of 39%

- PMLiVE

FDA receives Santhera and ReveraGen’s application for Duchenne muscular dystrophy treatment

The submission includes positive data from the pivotal phase 2b and four open-label studies

- PMLiVE

Alexion’s Ultomiris shows promise in neuromyelitis optica spectrum disorder phase 3 trial

Ultomiris-treated patients showed zero relapses with a median treatment duration of 73 weeks

- PMLiVE

ICR study reveals how cancers can evolve without relying on DNA mutations

The researchers found that epigenetic changes play a key role in how cancers adapt and evolve

Springer Nature Oncologists survey report 202

[Free Report] The What, How, and When of creating content for oncologists

Create content marketing that really engages healthcare professionals.

Springer Nature

- PMLiVE

AstraZeneca’s two advanced breast cancer trials meet primary endpoints

Both trials showed significant improvement in progression-free survival

- PMLiVE

AstraZeneca’s Imjudo/Imfinzi combination approved by FDA for unresectable liver cancer

Phase 3 trial results demonstrated a 22% reduction in risk of death versus sorafenib

- PMLiVE

ICR study raises possibility of predicting drug resistance in advance

The researchers found that stomach cancers could develop resistance to ATR inhibitors

Full Panel Discussion: Closing The Gaps In Patient-Centricity

On 11th September, the Medscape team came together at the Eiffel Tower for an exciting event attended by expert faculty, patient advocates and more than a hundred supporters of our...

Medscape Education Global

- PMLiVE

Kite and Refuge Biotechnologies join to develop potential treatments for blood cancer

The agreement bolsters Kite’s expertise in synthetic biology for oncology

- PMLiVE

ICR research shows blood tests could help guide the treatment for children’s cancer

Using liquid biopsies to monitor patients could determine how well treatment is working

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links